Japanese Encephalitis |
|
|
Clinical Trial: Immunogenicity and Safety Study of a Rapid Immunization Schedule with FSME-IMMUN 0.5 mL in Healthy Adults Aged 16 - 65 Years
This study has been completed.
|
Purpose
| Condition | Intervention | Phase |
|---|---|---|
| Encephalitis, Tick-Borne | Vaccine: Tick-Borne Encephalitis (TBE) Vaccine (Inactivated) | Phase IV |
MedlinePlus related topics: Encephalitis; Tick Bites; Viral Infections
Study Type: Interventional
Study Design: Prevention, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment
Official Title: Open Phase IV Clinical Study to Evaluate the Immunogenicity and Safety of a Rapid Immunization Schedule with FSME-IMMUN 0.5 mL in Healthy Adults Aged 16 - 65 Years
Study start: March 2004; Study completion: May 2004
Eligibility
Accepts Healthy Volunteers
Inclusion Criteria:
- Understanding the nature of the study, agreement to its provisions and written informed consent
- Written informed consent of subject´s parents / legal guardians (if subject is under 18 years of age)
- Aged >= 16 years (from the 16th birthday) to <= 65 years (to the last day before the 66th birthday)
- Clinically healthy, (i. e. the physician would have no reservations vaccinating with FSME-IMMUN 0.5 ml outside the scope of a clinical trial)
- Negative pregnancy test result at the first medical examination (if female and capable of bearing children)
- Agreeing to employ adequate birth control measures for the duration of the study (if female and capable of bearing children)
- Agreeing to keep a subject diary.
Exclusion Criteria:
- History of any previous TBE vaccination
- History of TBE infection
- History of infection with other flaviviruses
- History of vaccination against yellow fever and/or Japanese B-encephalitis
- History of allergic reactions, in particular to one of the components of the vaccine
- Suffering from a disease (e.g. autoimmune disease) or undergoing a form of treatment (e.g. systemic corticosteroids) that can be expected to influence immunological functions
- Known or suspected problem with drug or alcohol abuse (> 4 liters wine / week or equivalent level of other alcoholic beverages)
- Donation of blood or plasma within one month of study start
- Having received a blood transfusion or immunoglobulins within one month of study entry
- HIV positivity (an HIV test is not required specifically for the purpose of this study
- Simultaneous participation in another clinical trial including administration of an investigational product
- Participating in any other clinical study within six weeks prior to study start
- Participated in another Baxter vaccine study within the last six months (with the exception of follow-up studies)
- Pregnancy or lactation (if female)
- Having received any other vaccination within two weeks prior to study entry
Location Information
Belgium
SGS Biopharma Research Unit Stuivenberg, Antwerp, 2060, Belgium
Baxter BioScience Investigator, Principal Investigator, Baxter BioScience
More Information
Last Updated: September 12, 2005
Record first received: September 8, 2005
ClinicalTrials.gov Identifier: NCT00161954
Health Authority: Belgium: Directorate general for the protection of Public health: Medicines
ClinicalTrials.gov processed this record on 2005-09-13
Resources
- Japanese Encephalitis (Centers for Disease Control and Prevention)

Not Signed In -

